Search

Displaying results 821 - 830 of 9864 in total
  1. Drug

    Ziprasidone

    go.drugbank.com/drugs/DB00246
    ApprovedInvestigational

    [A180748] Although ziprasidone is classified as an atypical antipsychotic, it appears to have a lower incidence of metabolic adverse effects compared to other medications in the same class.[A190525]

    Categories: Dopamine D2 Receptor AntagonistsProducts: ZIPRASIDON AL 20MG HKP, ZIPRASIDON AL 40MG HKP
  2. Drug

    Ceftizoxime

    go.drugbank.com/drugs/DB01332
    ApprovedWithdrawn

    The drug is highly resistant to a broad spectrum of beta-lactamases and is active against a wide range of both aerobic and anaerobic gram-positive and gram-negative organisms. … A semisynthetic cephalosporin antibiotic which can be administered intravenously or by suppository.

  3. Drug

    Trifluridine

    go.drugbank.com/drugs/DB00432
    ApprovedInvestigational

    It is an active antiviral agent in ophthalmic solutions used mainly in the treatment of primary keratoconjunctivitis and recurrent epithelial keratitis due to herpes simplex virus. … Trifluridine is a fluorinated pyrimidine nucleoside that is structurally related to [idoxuridine] [A35271].

  4. Drug

    Riltozinameran

    go.drugbank.com/drugs/DB17095
    ApprovedInvestigational

    BA.4, BA.5) which, although similar, may behave differently from one another.[L43917] Riltozinameran is an mRNA vaccine encoding the S glycoprotein of SARS-CoV-2 Omicron variant lineage BA.1. … The Omicron variant of SARS-CoV-2 is a variant of concern that was first reported in November 2021.

    Mixtures: Comirnaty Original/omicron Ba.1
  5. Drug

    YKP-1358

    go.drugbank.com/drugs/DB06109
    Experimental

    YKP1358 is a novel serotonin (5-HT2A) and dopamine (D2) antagonist that has demonstrated potent activity in animals that relates to both positive and negative symptoms of schizophrenia. … In addition, the YKP1358 pharmacological profile suggests a very low potential for extrapyramidal side effects.

    Categories: Dopamine D2 Receptor Antagonists
  6. Drug

    Nortriptyline

    go.drugbank.com/drugs/DB00540
    ApprovedInvestigational

    Nortriptyline hydrochloride, the active metabolite of [amitriptyline], is a tricyclic antidepressant (TCA).

    Categories: Dopamine D2 Receptor Antagonists, P-glycoprotein substrates with a Narrow Therapeutic IndexSynonyms: 10,11-dihydro-N-methyl-5H-dibenzo[a,d]cycloheptene-Δ5,γ-propylamine, 3-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-N-methyl-1-propanamine
  7. Drug

    Levacetylmethadol

    go.drugbank.com/drugs/DB01227
    ApprovedWithdrawn

    Levacetylmethadol is a narcotic analgesic with a long onset and duration of action. It is used mainly in the treatment of narcotic dependence. … Levacetylmethadol was withdrawn from use in the European Union due to its high risk of QT interval prolongation. The production of levacetylmethadol in the US has ceased as well.[L44052,T862]

    Categories: Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A7 Substrates with a Narrow Therapeutic Index
  8. Drug

    Nateglinide

    go.drugbank.com/drugs/DB00731
    Approved

    Approximately one month of therapy is required before a decrease in fasting blood glucose is seen. Meglitnides may have a neutral effect on weight or cause a slight increase in weight. … Due to their mechanism of action, meglitinides may cause hypoglycemia although the risk is thought to be lower than that of sulfonylureas since their action is dependent on the presence of glucose.

    Mixtures: NAT-ALA 120/200 MG FILM KAPLI TABLET, 90 ADET, NAT-ALA 180/200 MG FILM KAPLI TABLET, 90 ADET
  9. Drug

    Somatrogon

    go.drugbank.com/drugs/DB14960
    ApprovedInvestigational

    [L39362] In October 2021, Health Canada approved somatrogon under the market name NGENLA as the long-term treatment of pediatric patients who have growth failure due to an inadequate secretion of endogenous … Somatrogon is a long-acting recombinant human growth hormone.

  10. Drug

    Hydrocortamate

    go.drugbank.com/drugs/DB00769
    Approved

    Hydrocortamate is a synthetic glucocorticoid used for its anti-inflammatory or immunosuppressive properties to treat inflammation due to corticosteroid-responsive dermatoses. … Glucocorticoids are a class of steroid hormones characterised by an ability to bind with the cortisol receptor and trigger a variety of important cardiovascular, metabolic, immunologic and homeostatic